AMARIN CORP PLCUK financial statements (2020 and earlier)

Company profile

Business Address FIRST FLOOR, BLOCK 3, THE OVAL,
DUBLIN, 00000
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6452497498107120192
Cash and cash equivalents6452497498107120192
Restricted cash and investments421111 
Receivables1166745201484
Inventory, net of allowances, customer advances and progress billings77583021191421
Inventory77583021191421
Other current assets     32
Other undisclosed current assets13337311
Total current assets:855378153146144145219
Noncurrent Assets
Inventory, Noncurrent      5
Operating lease, right-of-use asset9
Property, plant and equipment2000001
Intangible assets, net (including goodwill)1578991011
Intangible assets, net (excluding goodwill)1578991011
Other noncurrent assets1001234
Other undisclosed noncurrent assets   11181312
Total noncurrent assets:278821302633
TOTAL ASSETS:882386162167173171252
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7970431519148
Accounts payable50382561196
Accrued liabilities8209332 
Employee-related liabilities211287542
Deferred revenue2
Debt5034221615150
Derivative instruments and hedges, liabilities     0 
Deferred revenue and credits211 2
Contract with customer, liability1
Other liabilities17856423
Other undisclosed current liabilities9444373812924
Total current liabilities:24215710976514038
Noncurrent Liabilities
Long-term debt and lease obligation9467185929088
Long-term debt, excluding current maturities 467185929088
Capital lease obligations     0
Operating lease, liability9
Liabilities, other than long-term debt223018152281
Deferred revenue and credits171413  
Deferred revenue19
Contract with customer, liability19
Other liabilities41111001
Derivative instruments and hedges, liabilities    87 
Other undisclosed noncurrent liabilities  29 139122160
Total noncurrent liabilities:3276118100252219249
Total liabilities:274233227176303260286
Stockholders' equity
Stockholders' equity attributable to parent608152(65)(9)(129)(88)(34)
Preferred stock2222242424  
Common stock269247209207150143141
Treasury stock, value(36)(10)(4)(1)(0)(0)(0)
Additional paid in capital1,7641,283978965816739739
Accumulated deficit(1,411)(1,389)(1,272)(1,204)(1,119)(970)(914)
Total stockholders' equity:608152(65)(9)(129)(88)(34)
TOTAL LIABILITIES AND EQUITY:882386162167173171252

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues430229181130825426
Revenue, net18113082  
Cost of revenue
(Cost of Goods and Services Sold)
(96)(55)(45)(34)(28)(41)(26)
Other undisclosed gross profit     20 
Gross profit:3341751369654340
Operating expenses(358)(283)(182)(161)(152)(130)(208)
Other undisclosed operating income      26
Operating loss:(24)(108)(46)(66)(98)(96)(182)
Nonoperating income (expense)811(0)(0)10(1)
Investment income, nonoperating8100060
Other nonoperating income (expense)(0)(0)0(0)(0)4(1)
Interest and debt expense(7)(9)(10)(19)(19)19(34)
Other undisclosed income from continuing operations before equity method investments, income taxes     748
Loss from continuing operations before equity method investments, income taxes:(22)(116)(55)(85)(117)(59)(169)
Other undisclosed income (loss) from continuing operations before income taxes   8(1)  
Loss from continuing operations before income taxes:(22)(116)(55)(76)(118)(59)(169)
Income tax expense (benefit)(0)(0)(13)(10)333
Net loss attributable to parent:(23)(116)(68)(86)(115)(56)(166)
Preferred stock dividends and other adjustments    (1)  
Other undisclosed net loss available to common stockholders, basic    (33)  
Net loss available to common stockholders, basic:(23)(116)(68)(86)(149)(56)(166)
Dilutive securities, effect on basic earnings per share     (7) 
Other undisclosed net loss available to common stockholders, diluted      (48)
Net loss available to common stockholders, diluted:(23)(116)(68)(86)(149)(63)(214)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(23)(116)(68)(86)(115)(56)(166)
Comprehensive loss, net of tax, attributable to parent:(23)(116)(68)(86)(115)(56)(166)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: